At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 50 enrolled
Drug / intervention
Lithium Carbonatedrug
Likely dose
Lithium Carbonate 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Lithium Efficacy Against Chemotherapy Induced Neutropenia in Breast Cancer Patients
In Brief
A Phase 3 clinical trial evaluating Lithium Carbonate for Neutropenia. Completed, enrolled 50 participants across 1 site.
Detailed Summary
Using Lithium Carbonate to decrease incidence of neutropenia caused by using chemotherapy regimen in breast cancer patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeutropenia
CountriesEgypt
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
Enrollment StartAug 2020
First PostedFeb 2022
Primary CompletionApr 2022
Study CompletionJun 2022
TodayJul 2026
First PostedFeb 3, 2022
Enrollment StartAug 1, 2020
Primary CompletionApr 1, 2022
Study CompletionJun 1, 2022
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 4.4 years ago
Interventions
Lithium Carbonatedrug
400 mg tablet in controlled released formula